The discovery of the Estrogen Receptor Beta (ERβ) in 1996 opened new perspectives in the diagnostics and therapy of different types of cancer. Here, we present a review of the present research knowledge about its role in endocrine-related cancers: breast, prostate, and thyroid, and colorectal cancers. We also discuss the reasons for the controversy of its role in carcinogenesis and why it is still not in use as a biomarker in clinical practice. Given that the diagnostics and therapy would benefit from the introduction of new biomarkers, we suggest ways to overcome the contradictions in elucidating the role of ERβ.
TY - JOUR
AU - Božović, Ana M.
AU - Mandušić, Vesna
AU - Todorović, Lidija
AU - Krajnović, Milena M.
PY - 2021
UR - https://vinar.vin.bg.ac.rs/handle/123456789/9560
AB - The discovery of the Estrogen Receptor Beta (ERβ) in 1996 opened new perspectives in the diagnostics and therapy of different types of cancer. Here, we present a review of the present research knowledge about its role in endocrine-related cancers: breast, prostate, and thyroid, and colorectal cancers. We also discuss the reasons for the controversy of its role in carcinogenesis and why it is still not in use as a biomarker in clinical practice. Given that the diagnostics and therapy would benefit from the introduction of new biomarkers, we suggest ways to overcome the contradictions in elucidating the role of ERβ.
T2 - International Journal of Molecular Sciences
T1 - Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases
VL - 22
IS - 4
SP - 1656
DO - 10.3390/ijms22041656
ER -
@article{
author = "Božović, Ana M. and Mandušić, Vesna and Todorović, Lidija and Krajnović, Milena M.",
year = "2021",
abstract = "The discovery of the Estrogen Receptor Beta (ERβ) in 1996 opened new perspectives in the diagnostics and therapy of different types of cancer. Here, we present a review of the present research knowledge about its role in endocrine-related cancers: breast, prostate, and thyroid, and colorectal cancers. We also discuss the reasons for the controversy of its role in carcinogenesis and why it is still not in use as a biomarker in clinical practice. Given that the diagnostics and therapy would benefit from the introduction of new biomarkers, we suggest ways to overcome the contradictions in elucidating the role of ERβ.",
journal = "International Journal of Molecular Sciences",
title = "Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases",
volume = "22",
number = "4",
pages = "1656",
doi = "10.3390/ijms22041656"
}
Božović, A. M., Mandušić, V., Todorović, L.,& Krajnović, M. M.. (2021). Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases. in International Journal of Molecular Sciences, 22(4), 1656.
https://doi.org/10.3390/ijms22041656
Božović AM, Mandušić V, Todorović L, Krajnović MM. Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases. in International Journal of Molecular Sciences. 2021;22(4):1656.
doi:10.3390/ijms22041656 .
Božović, Ana M., Mandušić, Vesna, Todorović, Lidija, Krajnović, Milena M., "Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases" in International Journal of Molecular Sciences, 22, no. 4 (2021):1656,
https://doi.org/10.3390/ijms22041656 . .
